This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-125a-5p | ABHD2 | -0.31 | 0.3708 | 0.63 | 0.15716 | miRanda; mirMAP | -0.27 | 0.00546 | NA | |
2 | hsa-miR-125a-5p | ABHD3 | -0.31 | 0.3708 | 0.21 | 0.58467 | PITA; miRanda | -0.18 | 0.02803 | NA | |
3 | hsa-miR-141-3p | ABL1 | 1.13 | 0.09667 | -0.28 | 0.25357 | MirTarget | -0.12 | 0 | NA | |
4 | hsa-miR-19a-3p | ABL1 | -1.4 | 0.00391 | -0.28 | 0.25357 | mirMAP | -0.11 | 0.00272 | NA | |
5 | hsa-miR-29a-3p | ABL1 | -0.39 | 0.22665 | -0.28 | 0.25357 | miRNAWalker2 validate; miRNATAP | -0.21 | 0.00019 | NA | |
6 | hsa-miR-29a-5p | ABL1 | -0.6 | 0.06643 | -0.28 | 0.25357 | MirTarget | -0.12 | 0.02372 | NA | |
7 | hsa-miR-29b-3p | ABL1 | -0.39 | 0.34358 | -0.28 | 0.25357 | miRNATAP | -0.19 | 1.0E-5 | NA | |
8 | hsa-miR-29c-3p | ABL1 | -0.13 | 0.74361 | -0.28 | 0.25357 | miRNATAP | -0.15 | 0.0004 | NA | |
9 | hsa-miR-30b-5p | ABL1 | -0.68 | 0.07316 | -0.28 | 0.25357 | MirTarget; miRNATAP | -0.17 | 0.0002 | NA | |
10 | hsa-miR-30d-5p | ABL1 | -0.01 | 0.97473 | -0.28 | 0.25357 | MirTarget; miRNATAP | -0.15 | 0.01552 | NA | |
11 | hsa-miR-423-5p | ABL1 | -0.67 | 0.05556 | -0.28 | 0.25357 | MirTarget | -0.12 | 0.017 | NA | |
12 | hsa-miR-125a-5p | ACPP | -0.31 | 0.3708 | 0.84 | 0.23008 | MirTarget; miRanda | -0.61 | 6.0E-5 | NA | |
13 | hsa-miR-125a-5p | ACTBL2 | -0.31 | 0.3708 | 1.45 | 0.14365 | miRanda | -0.65 | 0.00258 | NA | |
14 | hsa-miR-125a-5p | ACTG2 | -0.31 | 0.3708 | 0.67 | 0.55281 | miRanda | -0.66 | 0.00735 | NA | |
15 | hsa-miR-125a-5p | ACTL6A | -0.31 | 0.3708 | 0.27 | 0.19205 | miRanda | -0.18 | 2.0E-5 | NA | |
16 | hsa-miR-125a-5p | ACTN4 | -0.31 | 0.3708 | 0.21 | 0.5222 | mirMAP | -0.22 | 0.0019 | NA | |
17 | hsa-miR-125a-5p | ADAM9 | -0.31 | 0.3708 | 0.41 | 0.38674 | PITA; miRanda | -0.25 | 0.01649 | NA | |
18 | hsa-miR-125a-5p | ADAMTS14 | -0.31 | 0.3708 | -0.08 | 0.91758 | miRanda; mirMAP | -0.68 | 2.0E-5 | NA | |
19 | hsa-miR-125a-5p | ADAMTS9 | -0.31 | 0.3708 | -0.6 | 0.25854 | miRanda | -0.26 | 0.02448 | NA | |
20 | hsa-miR-125a-5p | ADAP1 | -0.31 | 0.3708 | 1.46 | 0.03319 | mirMAP | -0.78 | 0 | NA | |
21 | hsa-miR-125a-5p | ADH5 | -0.31 | 0.3708 | 0.05 | 0.76619 | miRanda | -0.11 | 0.00468 | NA | |
22 | hsa-miR-125a-5p | ADM2 | -0.31 | 0.3708 | 0.38 | 0.58067 | mirMAP | -0.82 | 0 | NA | |
23 | hsa-miR-125a-5p | AEN | -0.31 | 0.3708 | 0.28 | 0.32652 | miRanda | -0.18 | 0.00325 | NA | |
24 | hsa-miR-125a-5p | AGTRAP | -0.31 | 0.3708 | -0.09 | 0.79335 | miRNAWalker2 validate; miRanda | -0.2 | 0.00471 | NA | |
25 | hsa-miR-125a-5p | AIFM1 | -0.31 | 0.3708 | 0.08 | 0.68492 | miRanda | -0.11 | 0.00731 | NA | |
26 | hsa-miR-125a-5p | AKAP13 | -0.31 | 0.3708 | -0.44 | 0.16463 | miRanda | -0.23 | 0.00085 | NA | |
27 | hsa-miR-125a-5p | ALDH1A3 | -0.31 | 0.3708 | 0.26 | 0.72786 | miRanda | -0.38 | 0.02042 | NA | |
28 | hsa-miR-125a-5p | ALPK1 | -0.31 | 0.3708 | -0.37 | 0.36057 | miRanda | -0.52 | 0 | NA | |
29 | hsa-miR-26b-5p | ANAPC1 | -1.22 | 0.00085 | 0.14 | 0.57801 | miRNAWalker2 validate | -0.16 | 0.00096 | NA | |
30 | hsa-miR-100-5p | ANAPC11 | 1.03 | 0.03044 | 0.33 | 0.27929 | miRNAWalker2 validate | -0.29 | 0 | NA | |
31 | hsa-miR-766-3p | ANAPC11 | -1.21 | 0.00153 | 0.33 | 0.27929 | MirTarget | -0.22 | 0.00013 | NA | |
32 | hsa-miR-542-3p | ANAPC2 | -0.89 | 0.02064 | -0.2 | 0.38656 | miRanda | -0.14 | 0.00174 | NA | |
33 | hsa-miR-30a-5p | ANAPC5 | -0.59 | 0.17531 | -0.12 | 0.49214 | miRNAWalker2 validate | -0.11 | 8.0E-5 | NA | |
34 | hsa-miR-30c-2-3p | ANAPC7 | -0.62 | 0.13013 | -0.02 | 0.91567 | MirTarget | -0.12 | 0.0001 | NA | |
35 | hsa-miR-125a-5p | ANKS6 | -0.31 | 0.3708 | 0.39 | 0.20456 | MirTarget | -0.17 | 0.00994 | NA | |
36 | hsa-miR-125a-5p | ANO6 | -0.31 | 0.3708 | 0.05 | 0.90255 | miRanda | -0.4 | 0 | NA | |
37 | hsa-miR-125a-5p | ANPEP | -0.31 | 0.3708 | -0.43 | 0.66538 | PITA; miRanda; miRNATAP | -0.59 | 0.00702 | NA | |
38 | hsa-miR-125a-5p | ANTXR2 | -0.31 | 0.3708 | 0.45 | 0.35344 | PITA | -0.51 | 0 | NA | |
39 | hsa-miR-125a-5p | ANXA11 | -0.31 | 0.3708 | 0.21 | 0.52584 | mirMAP | -0.38 | 0 | NA | |
40 | hsa-miR-125a-5p | APOD | -0.31 | 0.3708 | 0.71 | 0.376 | miRanda | -0.44 | 0.01111 | NA | |
41 | hsa-miR-125a-5p | ARHGAP11B | -0.31 | 0.3708 | 0.43 | 0.4759 | miRanda | -0.3 | 0.02232 | NA | |
42 | hsa-miR-125a-5p | ARHGAP27 | -0.31 | 0.3708 | 0.33 | 0.47834 | miRanda | -0.4 | 0.0001 | NA | |
43 | hsa-miR-125a-5p | ARHGEF2 | -0.31 | 0.3708 | 0.01 | 0.98121 | miRanda | -0.29 | 2.0E-5 | NA | |
44 | hsa-miR-125a-5p | ARMC7 | -0.31 | 0.3708 | 0.14 | 0.58061 | MirTarget; miRanda | -0.14 | 0.00867 | NA | |
45 | hsa-miR-125a-5p | ARPC5 | -0.31 | 0.3708 | -0.13 | 0.53299 | miRNAWalker2 validate | -0.11 | 0.01232 | NA | |
46 | hsa-miR-125a-5p | ARSD | -0.31 | 0.3708 | 0.54 | 0.1225 | miRanda | -0.2 | 0.00707 | NA | |
47 | hsa-miR-125a-5p | ARSI | -0.31 | 0.3708 | -0.05 | 0.95343 | MirTarget; miRanda | -0.58 | 0.0005 | NA | |
48 | hsa-miR-125a-5p | ASPH | -0.31 | 0.3708 | 0.98 | 0.03201 | miRanda | -0.37 | 0.00021 | NA | |
49 | hsa-miR-125a-5p | ATL2 | -0.31 | 0.3708 | -0 | 0.9982 | miRNAWalker2 validate; miRanda | -0.11 | 0.03608 | NA | |
50 | hsa-miR-18a-5p | ATM | -1.18 | 0.00436 | -0.78 | 0.04275 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.15 | 0.03076 | 23437304; 25963391; 23857602; 23229340 | MicroRNA 18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer; Through in silico search the 3'UTR of Ataxia telangiectasia mutated ATM contains a conserved miR-18a binding site; Expression of ATM was down-regulated in CRC tumors p<0.0001 and inversely correlated with miR-18a expression r = -0.4562 p<0.01; This was further confirmed by the down-regulation of ATM protein by miR-18a; As ATM is a key enzyme in DNA damage repair we evaluated the effect of miR-18a on DNA double-strand breaks; miR-18a attenuates cellular repair of DNA double-strand breaks by directly suppressing ATM a key enzyme in DNA damage repair;However the upregulation of miR-18a suppressed the level of ataxia-telangiectasia mutated and attenuated DNA double-strand break repair after irradiation which re-sensitized the cervical cancer cells to radiotherapy by promoting apoptosis;Furthermore we used antisense oligonucleotides against micro RNAs miRNA or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression; Furthermore we identified that ERα activates miR-18a and -106a to downregulate ATM expression; We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer;MicroRNA 18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells; Previous studies showed that certain microRNAs including miR-18a potentially regulate ATM in cancer cells; However the mechanisms behind the modulation of ATM by miR-18a remain to be elucidated in colon cancer cells; In the present study we explored the impact of miR-18a on the autophagy process and ATM expression in HCT116 colon cancer cells; Western blotting and luciferase assays were implemented to explore the impact of miR-18a on ATM gene expression in HCT116 cells; Moreover miR-18a overexpression led to the upregulation of ATM expression and suppression of mTORC1 activity; Results of the present study pertaining to the role of miR-18a in regulating autophagy and ATM gene expression in colon cancer cells revealed a novel function for miR-18a in a critical cellular event and on a crucial gene with significant impacts in cancer development progression treatment and in other diseases |
51 | hsa-miR-455-5p | ATM | -0.23 | 0.54044 | -0.78 | 0.04275 | miRanda | -0.3 | 7.0E-5 | NA | |
52 | hsa-miR-301a-3p | ATR | -0.76 | 0.09613 | -0.04 | 0.82153 | mirMAP | -0.1 | 0.00132 | NA | |
53 | hsa-miR-125a-5p | B2M | -0.31 | 0.3708 | -0.36 | 0.22342 | miRanda | -0.2 | 0.0024 | NA | |
54 | hsa-miR-125a-5p | B3GALNT2 | -0.31 | 0.3708 | 0.28 | 0.24769 | MirTarget; miRanda; miRNATAP | -0.13 | 0.01209 | NA | |
55 | hsa-miR-125a-5p | B3GNT3 | -0.31 | 0.3708 | 4.44 | 0 | MirTarget | -0.81 | 1.0E-5 | NA | |
56 | hsa-miR-125a-5p | B3GNT7 | -0.31 | 0.3708 | 0.91 | 0.22431 | mirMAP | -0.73 | 1.0E-5 | NA | |
57 | hsa-miR-125a-5p | B4GALT1 | -0.31 | 0.3708 | -0.2 | 0.59693 | miRanda | -0.47 | 0 | NA | |
58 | hsa-miR-125a-5p | BAK1 | -0.31 | 0.3708 | 0.35 | 0.26822 | miRNAWalker2 validate; PITA; miRanda; miRNATAP | -0.39 | 0 | NA | |
59 | hsa-miR-125a-5p | BATF2 | -0.31 | 0.3708 | 0 | 0.99425 | miRanda | -0.21 | 0.04307 | NA | |
60 | hsa-miR-125a-5p | BAZ1A | -0.31 | 0.3708 | -0.22 | 0.53161 | miRanda | -0.33 | 1.0E-5 | NA | |
61 | hsa-miR-125a-5p | BCAT1 | -0.31 | 0.3708 | -0.37 | 0.61191 | MirTarget | -0.43 | 0.00705 | NA | |
62 | hsa-miR-125a-5p | BCKDK | -0.31 | 0.3708 | -0.01 | 0.94665 | miRanda | -0.15 | 0.00057 | NA | |
63 | hsa-miR-125a-5p | BCL2L12 | -0.31 | 0.3708 | -0.07 | 0.87268 | miRanda; miRNATAP | -0.51 | 0 | NA | |
64 | hsa-miR-125a-5p | BCL2L14 | -0.31 | 0.3708 | 1.55 | 0.10771 | MirTarget; PITA; miRanda | -1.31 | 0 | NA | |
65 | hsa-miR-125a-5p | BIK | -0.31 | 0.3708 | 0.91 | 0.17202 | miRanda | -0.48 | 0.00101 | NA | |
66 | hsa-miR-125a-5p | BLZF1 | -0.31 | 0.3708 | 0.7 | 0.01024 | miRanda | -0.15 | 0.01388 | NA | |
67 | hsa-miR-125a-5p | BMP1 | -0.31 | 0.3708 | -0.01 | 0.9761 | mirMAP | -0.19 | 0.03832 | NA | |
68 | hsa-miR-125a-5p | BMPR1B | -0.31 | 0.3708 | 0.22 | 0.768 | MirTarget; miRNATAP | -0.92 | 0 | NA | |
69 | hsa-miR-125a-5p | BRCC3 | -0.31 | 0.3708 | 0.28 | 0.1857 | miRanda | -0.1 | 0.02579 | NA | |
70 | hsa-miR-125a-5p | BTN2A2 | -0.31 | 0.3708 | -1.12 | 0.00207 | miRanda | -0.25 | 0.00172 | NA | |
71 | hsa-miR-139-5p | BUB1 | -1.64 | 0.00654 | 0.75 | 0.2317 | miRanda | -0.35 | 0 | NA | |
72 | hsa-miR-324-5p | BUB1 | -0.99 | 0.00957 | 0.75 | 0.2317 | MirTarget | -0.27 | 0.02734 | NA | |
73 | hsa-miR-495-3p | BUB1 | -0.82 | 0.09306 | 0.75 | 0.2317 | MirTarget | -0.39 | 3.0E-5 | NA | |
74 | hsa-miR-543 | BUB1 | -1.03 | 0.07135 | 0.75 | 0.2317 | miRanda | -0.31 | 9.0E-5 | NA | |
75 | hsa-miR-543 | BUB1B | -1.03 | 0.07135 | 0.73 | 0.18404 | miRanda | -0.21 | 0.00376 | NA | |
76 | hsa-miR-125a-5p | C1RL | -0.31 | 0.3708 | -0.35 | 0.31475 | miRanda | -0.34 | 0 | NA | |
77 | hsa-miR-125a-5p | C2 | -0.31 | 0.3708 | -0.78 | 0.18449 | miRanda | -0.61 | 0 | NA | |
78 | hsa-miR-125a-5p | CANT1 | -0.31 | 0.3708 | 0.64 | 0.0479 | mirMAP | -0.36 | 0 | NA | |
79 | hsa-miR-125a-5p | CASP10 | -0.31 | 0.3708 | -0.18 | 0.62889 | mirMAP | -0.33 | 2.0E-5 | NA | |
80 | hsa-miR-125a-5p | CASP6 | -0.31 | 0.3708 | 0.22 | 0.45531 | miRanda | -0.34 | 0 | NA | |
81 | hsa-miR-125a-5p | CBLB | -0.31 | 0.3708 | -0.33 | 0.19169 | miRanda | -0.19 | 0.00051 | NA | |
82 | hsa-let-7b-5p | CCNA1 | 0.13 | 0.6518 | -0.49 | 0.55046 | miRNAWalker2 validate | -0.8 | 0.00011 | NA | |
83 | hsa-miR-30a-5p | CCNA1 | -0.59 | 0.17531 | -0.49 | 0.55046 | MirTarget | -0.31 | 0.02677 | NA | |
84 | hsa-miR-129-5p | CCNA2 | 1.01 | 0.36712 | 0.67 | 0.16545 | miRanda | -0.18 | 0 | NA | |
85 | hsa-miR-132-3p | CCNA2 | -0.19 | 0.63856 | 0.67 | 0.16545 | miRNAWalker2 validate | -0.36 | 5.0E-5 | NA | |
86 | hsa-miR-212-3p | CCNA2 | -0.37 | 0.45016 | 0.67 | 0.16545 | miRNAWalker2 validate | -0.21 | 0.004 | NA | |
87 | hsa-miR-218-5p | CCNA2 | -0.69 | 0.12531 | 0.67 | 0.16545 | MirTarget | -0.26 | 0.00083 | NA | |
88 | hsa-miR-29c-3p | CCNA2 | -0.13 | 0.74361 | 0.67 | 0.16545 | MirTarget | -0.28 | 0.00167 | NA | |
89 | hsa-miR-301a-3p | CCNA2 | -0.76 | 0.09613 | 0.67 | 0.16545 | miRNATAP | -0.2 | 0.00997 | NA | |
90 | hsa-miR-374a-5p | CCNA2 | -0.77 | 0.02145 | 0.67 | 0.16545 | mirMAP | -0.21 | 0.04649 | NA | |
91 | hsa-miR-98-5p | CCNA2 | -0.22 | 0.42277 | 0.67 | 0.16545 | miRNAWalker2 validate | -0.32 | 0.01832 | NA | |
92 | hsa-miR-132-3p | CCNB1 | -0.19 | 0.63856 | 1.05 | 0.01857 | miRNAWalker2 validate | -0.26 | 0.00151 | NA | |
93 | hsa-miR-139-5p | CCNB1 | -1.64 | 0.00654 | 1.05 | 0.01857 | miRanda | -0.24 | 0 | NA | |
94 | hsa-miR-212-3p | CCNB1 | -0.37 | 0.45016 | 1.05 | 0.01857 | miRNAWalker2 validate | -0.18 | 0.00662 | NA | |
95 | hsa-miR-496 | CCNB1 | -0.26 | 0.66888 | 1.05 | 0.01857 | miRanda | -0.13 | 0.0144 | NA | |
96 | hsa-miR-543 | CCNB1 | -1.03 | 0.07135 | 1.05 | 0.01857 | miRanda | -0.14 | 0.01214 | NA | |
97 | hsa-miR-23b-3p | CCNB2 | 0.01 | 0.97527 | 0.8 | 0.25181 | miRNAWalker2 validate | -0.65 | 0.00469 | NA | |
98 | hsa-miR-135a-5p | CCND1 | -0.2 | 0.83089 | 1.04 | 0.01709 | mirMAP | -0.1 | 0.00282 | NA | |
99 | hsa-miR-142-3p | CCND1 | -2.4 | 4.0E-5 | 1.04 | 0.01709 | miRanda | -0.11 | 0.04224 | 23619912 | Transfection of miR-142-3p mimics in colon cancer cells downregulated cyclin D1 expression induced G1 phase cell cycle arrest and elevated the sensitivity of the cells to 5-fluorouracil |
100 | hsa-miR-150-5p | CCND1 | -1.91 | 0.02035 | 1.04 | 0.01709 | mirMAP | -0.1 | 0.00937 | NA | |
101 | hsa-miR-15a-5p | CCND1 | -0.74 | 0.01074 | 1.04 | 0.01709 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.36 | 0.00124 | 22922827 | CCND1 has been found to be a target of miR-15a and miR-16-1 through analysis of complementary sequences between microRNAs and CCND1 mRNA; Moreover the transcription of CCND1 is suppressed by miR-15a and miR-16-1 via direct binding to the CCND1 3'-untranslated region 3'-UTR |
102 | hsa-miR-16-5p | CCND1 | -1.02 | 0.00033 | 1.04 | 0.01709 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.35 | 0.00208 | 23991964; 22922827; 18483394 | At the molecular level our results further revealed that cyclin D1 expression was negatively regulated by miR-16;CCND1 has been found to be a target of miR-15a and miR-16-1 through analysis of complementary sequences between microRNAs and CCND1 mRNA; Moreover the transcription of CCND1 is suppressed by miR-15a and miR-16-1 via direct binding to the CCND1 3'-untranslated region 3'-UTR;Truncation in CCND1 mRNA alters miR 16 1 regulation in mantle cell lymphoma; Furthermore we demonstrated that this truncation alters miR-16-1 binding sites and through the use of reporter constructs we were able to show that miR-16-1 regulates CCND1 mRNA expression; This study introduces the role of miR-16-1 in the regulation of CCND1 in MCL |
103 | hsa-miR-186-5p | CCND1 | -0.77 | 0.00203 | 1.04 | 0.01709 | mirMAP | -0.5 | 0.00012 | NA | |
104 | hsa-miR-195-5p | CCND1 | -0.69 | 0.07175 | 1.04 | 0.01709 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.23 | 0.00668 | 21350001; 26631043; 25823925 | Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497 miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer;MiR 195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1; The present study was to evaluate the level of miR-195 and cyclin D1 in CC tissues and cells; We further investigated the molecular mechanisms of miR-195 and cyclin D1 in CC cell lines HeLa and SiHa; Furthermore the expression of miR-195 was inversely proportional to that of cyclin D1 mRNA or protein p = 0.013 p = 0.015 respectively; However the inhibitor of miR-195 promoted the expression of cyclin D1 and cell proliferation; In conclusion our data suggest that miR-195 may have the potential role in treatment of CC patients as well as miR-195 is a novel regulator of invasiveness and tumorigenicity in CC cells by targeting cyclin D1;MicroRNA profiling identifies MiR 195 suppresses osteosarcoma cell metastasis by targeting CCND1; Meanwhile CCND1 was identified as the target gene of miR-195 and further studied; More importantly using real-time PCR we evaluated the expression of miR-195 and CCND1 in osteosarcoma samples from 107 frozen biopsy tissues and 99 formalin- or paraformalin-fixed paraffin-embedded FFPE tissues; Results indicated lowly expressed miR-195 or highly CCND1 correlated with positive overall survival and their expression inversely related to each other; In summary our study suggests miR-195 functions as a tumor metastasis suppressor gene by down-regulating CCND1 and can be used as a potential target in the treatment of osteosarcoma |
105 | hsa-miR-20b-5p | CCND1 | -1.45 | 0.00948 | 1.04 | 0.01709 | MirTarget; miRNATAP | -0.15 | 0.00755 | NA | |
106 | hsa-miR-296-5p | CCND1 | -1.02 | 0.0303 | 1.04 | 0.01709 | miRNAWalker2 validate | -0.19 | 0.00651 | 20485139 | Downregulation of miR-296 might inhibit growth of esophageal cancer cells in vitro and in vivo through regulation of cyclin D1 and p27 |
107 | hsa-miR-29c-3p | CCND1 | -0.13 | 0.74361 | 1.04 | 0.01709 | mirMAP | -0.24 | 0.00236 | NA | |
108 | hsa-miR-330-3p | CCND1 | 0.23 | 0.63792 | 1.04 | 0.01709 | mirMAP | -0.22 | 0.00098 | NA | |
109 | hsa-miR-338-3p | CCND1 | 0.51 | 0.34448 | 1.04 | 0.01709 | miRNAWalker2 validate; miRTarBase; miRanda | -0.13 | 0.0237 | NA | |
110 | hsa-miR-33a-3p | CCND1 | -1.71 | 0.00034 | 1.04 | 0.01709 | MirTarget | -0.14 | 0.03887 | NA | |
111 | hsa-miR-340-5p | CCND1 | -0.87 | 0.0362 | 1.04 | 0.01709 | mirMAP | -0.26 | 0.00064 | NA | |
112 | hsa-miR-374a-5p | CCND1 | -0.77 | 0.02145 | 1.04 | 0.01709 | MirTarget | -0.36 | 0.0002 | 27191497 | microRNA 374a suppresses colon cancer progression by directly reducing CCND1 to inactivate the PI3K/AKT pathway; Furthermore luciferase reporter assays confirmed that miR-374a could directly reduce CCND1; We examined miR-374a levels by in situ hybridization and its correlation with CCND1 expression in CRC tumor tissues; High miR-374a expression with low level of CCND1 was protective factor in CRC; Together these findings indicate that miR-374a inactivates the PI3K/AKT axis by inhibiting CCND1 suppressing of colon cancer progression |
113 | hsa-miR-374b-5p | CCND1 | -0.94 | 0.0014 | 1.04 | 0.01709 | miRNAWalker2 validate; MirTarget | -0.35 | 0.00167 | NA | |
114 | hsa-miR-495-3p | CCND1 | -0.82 | 0.09306 | 1.04 | 0.01709 | MirTarget | -0.22 | 0.00064 | NA | |
115 | hsa-miR-497-5p | CCND1 | -0.81 | 0.02071 | 1.04 | 0.01709 | MirTarget; miRNATAP | -0.18 | 0.04981 | 21350001 | Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497 miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer |
116 | hsa-miR-590-3p | CCND1 | -0.92 | 0.03456 | 1.04 | 0.01709 | mirMAP | -0.23 | 0.00179 | NA | |
117 | hsa-miR-7-1-3p | CCND1 | -0.73 | 0.0834 | 1.04 | 0.01709 | mirMAP | -0.34 | 1.0E-5 | NA | |
118 | hsa-miR-769-3p | CCND1 | -0.42 | 0.40382 | 1.04 | 0.01709 | mirMAP | -0.2 | 0.0019 | NA | |
119 | hsa-miR-9-5p | CCND1 | -0.04 | 0.94649 | 1.04 | 0.01709 | miRNAWalker2 validate | -0.16 | 0.00122 | NA | |
120 | hsa-let-7b-3p | CCND2 | -0.41 | 0.16777 | -0.32 | 0.53544 | mirMAP | -0.39 | 0.00252 | NA | |
121 | hsa-miR-10a-3p | CCND2 | -0.28 | 0.53841 | -0.32 | 0.53544 | mirMAP | -0.3 | 0.00038 | NA | |
122 | hsa-miR-16-2-3p | CCND2 | -1.03 | 0.00735 | -0.32 | 0.53544 | mirMAP | -0.21 | 0.03069 | NA | |
123 | hsa-miR-17-5p | CCND2 | -0.67 | 0.04231 | -0.32 | 0.53544 | miRNAWalker2 validate; miRTarBase; TargetScan; miRNATAP | -0.37 | 0.00132 | NA | |
124 | hsa-miR-181a-2-3p | CCND2 | -0.83 | 0.04338 | -0.32 | 0.53544 | mirMAP | -0.45 | 0 | NA | |
125 | hsa-miR-196a-5p | CCND2 | 2.84 | 0.01406 | -0.32 | 0.53544 | miRNAWalker2 validate | -0.14 | 2.0E-5 | NA | |
126 | hsa-miR-20a-5p | CCND2 | -0.39 | 0.26959 | -0.32 | 0.53544 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.33 | 0.00206 | NA | |
127 | hsa-miR-21-3p | CCND2 | -0.44 | 0.44935 | -0.32 | 0.53544 | mirMAP | -0.26 | 6.0E-5 | NA | |
128 | hsa-miR-224-3p | CCND2 | -0.91 | 0.10932 | -0.32 | 0.53544 | mirMAP | -0.25 | 0.00011 | NA | |
129 | hsa-miR-2355-3p | CCND2 | -0.91 | 0.0288 | -0.32 | 0.53544 | miRNATAP | -0.36 | 7.0E-5 | NA | |
130 | hsa-miR-28-5p | CCND2 | -0.53 | 0.03042 | -0.32 | 0.53544 | miRanda | -0.49 | 0.00234 | NA | |
131 | hsa-miR-29a-3p | CCND2 | -0.39 | 0.22665 | -0.32 | 0.53544 | MirTarget; miRNATAP | -0.24 | 0.04604 | 22330340; 24130168 | In addition to CCND2 miR-29 also targets E2F7 another cell cycle regulator;We further demonstrated that miR-29 family acted as tumor suppressors through targeting CCND2 and matrix metalloproteinase-2 genes in GC |
132 | hsa-miR-30a-3p | CCND2 | -0.7 | 0.13951 | -0.32 | 0.53544 | mirMAP | -0.23 | 0.00501 | NA | |
133 | hsa-miR-708-3p | CCND2 | -0.29 | 0.54382 | -0.32 | 0.53544 | mirMAP | -0.17 | 0.03697 | NA | |
134 | hsa-miR-93-5p | CCND2 | -0.47 | 0.13146 | -0.32 | 0.53544 | miRNATAP | -0.35 | 0.00536 | NA | |
135 | hsa-let-7b-5p | CCND3 | 0.13 | 0.6518 | 0.09 | 0.75989 | miRNAWalker2 validate | -0.25 | 0.0004 | NA | |
136 | hsa-miR-26a-5p | CCNE1 | -0.6 | 0.02459 | 0.83 | 0.08087 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.38 | 0.00465 | 22094936 | Cell cycle regulation and CCNE1 and CDC2 were the only significant overlapping pathway and genes differentially expressed between tumors with high and low levels of miR-26a and EZH2 respectively; Low mRNA levels of EZH2 CCNE1 and CDC2 and high levels of miR-26a are associated with favorable outcome on tamoxifen |
137 | hsa-miR-874-3p | CCNE1 | -0.13 | 0.77247 | 0.83 | 0.08087 | MirTarget | -0.16 | 0.03199 | NA | |
138 | hsa-miR-30b-5p | CCNE2 | -0.68 | 0.07316 | 0.43 | 0.30154 | miRNAWalker2 validate; miRTarBase | -0.16 | 0.04889 | 22384020 | A luciferase-based reporter assay demonstrated that miR-30b post-transcriptionally reduced 27% p = 0.005 of the gene expression by interacting with two binding sites in the 3'-UTR of CCNE2; The upregulation of miR-30b by trastuzumab may play a biological role in trastuzumab-induced cell growth inhibition by targeting CCNE2 |
139 | hsa-miR-369-3p | CCNE2 | -0.83 | 0.17364 | 0.43 | 0.30154 | PITA | -0.14 | 0.00391 | NA | |
140 | hsa-miR-23a-3p | CCNH | -0.22 | 0.39943 | -0.01 | 0.96731 | MirTarget | -0.14 | 0.00863 | NA | |
141 | hsa-miR-23b-3p | CCNH | 0.01 | 0.97527 | -0.01 | 0.96731 | MirTarget | -0.12 | 0.04997 | NA | |
142 | hsa-miR-125a-5p | CCT2 | -0.31 | 0.3708 | 0.18 | 0.4333 | miRanda | -0.12 | 0.01365 | NA | |
143 | hsa-miR-125a-5p | CD248 | -0.31 | 0.3708 | 0.06 | 0.91415 | PITA; miRanda; miRNATAP | -0.3 | 0.01514 | NA | |
144 | hsa-miR-125a-5p | CD276 | -0.31 | 0.3708 | -0.03 | 0.92101 | miRanda | -0.27 | 0.00013 | NA | |
145 | hsa-miR-125a-5p | CD300LF | -0.31 | 0.3708 | -1.89 | 0.00608 | miRNATAP | -0.3 | 0.0488 | NA | |
146 | hsa-miR-125a-5p | CDA | -0.31 | 0.3708 | 1.34 | 0.11216 | miRanda | -0.54 | 0.00357 | NA | |
147 | hsa-let-7a-3p | CDC14A | -0.95 | 0.00672 | -0.8 | 0.05646 | mirMAP | -0.24 | 0.00658 | NA | |
148 | hsa-miR-141-3p | CDC14A | 1.13 | 0.09667 | -0.8 | 0.05646 | TargetScan; miRNATAP | -0.23 | 0 | NA | |
149 | hsa-miR-192-5p | CDC14A | 2.1 | 0.00233 | -0.8 | 0.05646 | miRNAWalker2 validate | -0.15 | 0.00099 | NA | |
150 | hsa-miR-194-5p | CDC14A | 2.55 | 0.00024 | -0.8 | 0.05646 | miRNATAP | -0.14 | 0.00173 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | MITOTIC CELL CYCLE | 89 | 766 | 7.005e-34 | 3.259e-30 |
2 | CELL CYCLE | 116 | 1316 | 7.187e-33 | 1.672e-29 |
3 | CELL CYCLE PROCESS | 104 | 1081 | 1.603e-32 | 2.486e-29 |
4 | REGULATION OF CELL CYCLE | 93 | 949 | 1.371e-29 | 1.595e-26 |
5 | REGULATION OF CELL CYCLE PHASE TRANSITION | 53 | 321 | 1.27e-27 | 1.181e-24 |
6 | REGULATION OF MITOTIC CELL CYCLE | 61 | 468 | 6.407e-26 | 4.969e-23 |
7 | CELL CYCLE PHASE TRANSITION | 46 | 255 | 8.788e-26 | 5.842e-23 |
8 | CELL CYCLE G1 S PHASE TRANSITION | 32 | 111 | 5.777e-25 | 2.987e-22 |
9 | G1 S TRANSITION OF MITOTIC CELL CYCLE | 32 | 111 | 5.777e-25 | 2.987e-22 |
10 | REGULATION OF CELL CYCLE PROCESS | 64 | 558 | 4.738e-24 | 2.205e-21 |
11 | CELL CYCLE CHECKPOINT | 38 | 194 | 8.294e-23 | 3.508e-20 |
12 | NEGATIVE REGULATION OF CELL CYCLE | 52 | 433 | 1.437e-20 | 5.573e-18 |
13 | NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 36 | 199 | 1.892e-20 | 6.771e-18 |
14 | CELL DIVISION | 53 | 460 | 4.005e-20 | 1.331e-17 |
15 | MITOTIC CELL CYCLE CHECKPOINT | 30 | 139 | 1.613e-19 | 5.003e-17 |
16 | NEGATIVE REGULATION OF CELL CYCLE PROCESS | 36 | 214 | 2.332e-19 | 6.783e-17 |
17 | REGULATION OF TRANSFERASE ACTIVITY | 76 | 946 | 5.925e-19 | 1.622e-16 |
18 | NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 30 | 146 | 7.1e-19 | 1.835e-16 |
19 | DNA INTEGRITY CHECKPOINT | 28 | 146 | 7.189e-17 | 1.76e-14 |
20 | POSITIVE REGULATION OF CELL CYCLE | 40 | 332 | 4.179e-16 | 9.722e-14 |
21 | REGULATION OF PROTEIN UBIQUITINATION INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 23 | 103 | 1.31e-15 | 2.903e-13 |
22 | MITOTIC NUCLEAR DIVISION | 41 | 361 | 1.414e-15 | 2.991e-13 |
23 | ANAPHASE PROMOTING COMPLEX DEPENDENT CATABOLIC PROCESS | 20 | 77 | 4.154e-15 | 8.404e-13 |
24 | REGULATION OF LIGASE ACTIVITY | 24 | 130 | 2.943e-14 | 5.706e-12 |
25 | NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 21 | 98 | 5.501e-14 | 1.024e-11 |
26 | POSITIVE REGULATION OF LIGASE ACTIVITY | 22 | 110 | 6.258e-14 | 1.096e-11 |
27 | REGULATION OF PROTEIN MODIFICATION PROCESS | 97 | 1710 | 6.362e-14 | 1.096e-11 |
28 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 38 | 351 | 7.467e-14 | 1.241e-11 |
29 | REGULATION OF PROTEIN CATABOLIC PROCESS | 40 | 393 | 1.244e-13 | 1.996e-11 |
30 | NEGATIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 24 | 139 | 1.384e-13 | 2.146e-11 |
31 | POSITIVE REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 28 | 196 | 1.751e-13 | 2.628e-11 |
32 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 51 | 616 | 1.82e-13 | 2.647e-11 |
33 | ORGANELLE FISSION | 45 | 496 | 2.179e-13 | 2.982e-11 |
34 | POSITIVE REGULATION OF PROTEOLYSIS | 38 | 363 | 2.164e-13 | 2.982e-11 |
35 | G1 DNA DAMAGE CHECKPOINT | 18 | 73 | 2.652e-13 | 3.526e-11 |
36 | REGULATION OF PROTEIN MODIFICATION BY SMALL PROTEIN CONJUGATION OR REMOVAL | 33 | 280 | 3.18e-13 | 3.999e-11 |
37 | POSITIVE REGULATION OF CELL CYCLE PROCESS | 31 | 247 | 3.109e-13 | 3.999e-11 |
38 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 71 | 1087 | 3.785e-13 | 4.634e-11 |
39 | REGULATION OF CELL PROLIFERATION | 87 | 1496 | 4.171e-13 | 4.976e-11 |
40 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 50 | 616 | 6.745e-13 | 7.846e-11 |
41 | MITOTIC DNA INTEGRITY CHECKPOINT | 20 | 100 | 8.745e-13 | 9.925e-11 |
42 | REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 32 | 274 | 9.417e-13 | 1.043e-10 |
43 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 86 | 1518 | 2.41e-12 | 2.607e-10 |
44 | NEGATIVE REGULATION OF CELL PROLIFERATION | 50 | 643 | 3.329e-12 | 3.521e-10 |
45 | REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 23 | 147 | 3.803e-12 | 3.847e-10 |
46 | PROTEASOMAL PROTEIN CATABOLIC PROCESS | 31 | 271 | 3.727e-12 | 3.847e-10 |
47 | SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE | 19 | 96 | 3.978e-12 | 3.938e-10 |
48 | REGULATION OF CELL DIVISION | 31 | 272 | 4.108e-12 | 3.982e-10 |
49 | POSITIVE REGULATION OF CELL CYCLE ARREST | 18 | 85 | 4.375e-12 | 4.154e-10 |
50 | REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 19 | 97 | 4.83e-12 | 4.495e-10 |
51 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 95 | 1791 | 6.105e-12 | 5.57e-10 |
52 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 69 | 1135 | 2.264e-11 | 2.026e-09 |
53 | POSITIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 25 | 192 | 2.824e-11 | 2.479e-09 |
54 | REGULATION OF CELL CYCLE ARREST | 19 | 108 | 3.513e-11 | 3.027e-09 |
55 | REGULATION OF PROTEOLYSIS | 51 | 711 | 3.901e-11 | 3.301e-09 |
56 | POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 29 | 263 | 4.615e-11 | 3.835e-09 |
57 | CELL CYCLE ARREST | 22 | 154 | 7.077e-11 | 5.777e-09 |
58 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 81 | 1492 | 9.714e-11 | 7.793e-09 |
59 | REGULATION OF SISTER CHROMATID SEGREGATION | 15 | 67 | 1.165e-10 | 9.187e-09 |
60 | REGULATION OF ORGANELLE ORGANIZATION | 68 | 1178 | 3.025e-10 | 2.346e-08 |
61 | REGULATION OF CATABOLIC PROCESS | 50 | 731 | 3.234e-10 | 2.467e-08 |
62 | REGULATION OF CHROMOSOME SEGREGATION | 16 | 85 | 4.414e-10 | 3.312e-08 |
63 | POSITIVE REGULATION OF FIBROBLAST PROLIFERATION | 13 | 53 | 6.038e-10 | 4.39e-08 |
64 | POSITIVE REGULATION OF CELL DEATH | 44 | 605 | 6.017e-10 | 4.39e-08 |
65 | SISTER CHROMATID SEGREGATION | 22 | 176 | 9.714e-10 | 6.954e-08 |
66 | TISSUE DEVELOPMENT | 79 | 1518 | 1.237e-09 | 8.723e-08 |
67 | REGULATION OF NUCLEAR DIVISION | 21 | 163 | 1.34e-09 | 9.307e-08 |
68 | REGULATION OF FIBROBLAST PROLIFERATION | 15 | 81 | 1.971e-09 | 1.349e-07 |
69 | CELLULAR RESPONSE TO STRESS | 80 | 1565 | 2.176e-09 | 1.468e-07 |
70 | SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR | 18 | 127 | 4.36e-09 | 2.898e-07 |
71 | CELL PROLIFERATION | 45 | 672 | 5.034e-09 | 3.266e-07 |
72 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 47 | 720 | 5.054e-09 | 3.266e-07 |
73 | REGULATION OF KINASE ACTIVITY | 49 | 776 | 6.875e-09 | 4.323e-07 |
74 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 58 | 1004 | 6.854e-09 | 4.323e-07 |
75 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 91 | 1929 | 7.768e-09 | 4.819e-07 |
76 | REGULATION OF CELL DEATH | 75 | 1472 | 8.643e-09 | 5.292e-07 |
77 | RESPONSE TO OXYGEN LEVELS | 28 | 311 | 1.004e-08 | 6.07e-07 |
78 | INTRACELLULAR SIGNAL TRANSDUCTION | 78 | 1572 | 1.322e-08 | 7.885e-07 |
79 | REGULATION OF TRANSCRIPTION INVOLVED IN G1 S TRANSITION OF MITOTIC CELL CYCLE | 9 | 27 | 1.416e-08 | 8.339e-07 |
80 | CELL DEATH | 57 | 1001 | 1.554e-08 | 8.956e-07 |
81 | REGULATION OF CHROMOSOME ORGANIZATION | 26 | 278 | 1.559e-08 | 8.956e-07 |
82 | CELL CYCLE G2 M PHASE TRANSITION | 18 | 138 | 1.665e-08 | 9.447e-07 |
83 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 87 | 1848 | 1.957e-08 | 1.097e-06 |
84 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 50 | 829 | 2.106e-08 | 1.167e-06 |
85 | NUCLEAR CHROMOSOME SEGREGATION | 23 | 228 | 2.608e-08 | 1.428e-06 |
86 | RESPONSE TO GROWTH FACTOR | 35 | 475 | 2.646e-08 | 1.432e-06 |
87 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 13 | 71 | 2.734e-08 | 1.462e-06 |
88 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 85 | 1805 | 2.907e-08 | 1.52e-06 |
89 | DNA REPLICATION INITIATION | 9 | 29 | 2.89e-08 | 1.52e-06 |
90 | PROTEIN PHOSPHORYLATION | 54 | 944 | 3.298e-08 | 1.705e-06 |
91 | RESPONSE TO ABIOTIC STIMULUS | 57 | 1024 | 3.418e-08 | 1.747e-06 |
92 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 38 | 552 | 4.033e-08 | 2.04e-06 |
93 | IMMUNE SYSTEM DEVELOPMENT | 39 | 582 | 5.452e-08 | 2.728e-06 |
94 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 29 | 360 | 6.401e-08 | 3.169e-06 |
95 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 34 | 470 | 6.558e-08 | 3.212e-06 |
96 | EPITHELIUM DEVELOPMENT | 53 | 945 | 8.458e-08 | 4.1e-06 |
97 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 19 | 171 | 9.278e-08 | 4.451e-06 |
98 | G2 DNA DAMAGE CHECKPOINT | 9 | 33 | 1.015e-07 | 4.821e-06 |
99 | DNA REPLICATION | 21 | 208 | 1.039e-07 | 4.883e-06 |
100 | APOPTOTIC SIGNALING PATHWAY | 25 | 289 | 1.354e-07 | 6.302e-06 |
101 | PROTEIN CATABOLIC PROCESS | 38 | 579 | 1.384e-07 | 6.323e-06 |
102 | POSITIVE REGULATION OF CATABOLIC PROCESS | 30 | 395 | 1.386e-07 | 6.323e-06 |
103 | REGULATION OF IMMUNE SYSTEM PROCESS | 69 | 1403 | 1.439e-07 | 6.5e-06 |
104 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 82 | 1784 | 1.507e-07 | 6.743e-06 |
105 | CHROMOSOME SEGREGATION | 24 | 272 | 1.672e-07 | 7.408e-06 |
106 | DNA METABOLIC PROCESS | 45 | 758 | 1.751e-07 | 7.686e-06 |
107 | POSITIVE REGULATION OF CELL COMMUNICATION | 73 | 1532 | 2.059e-07 | 8.956e-06 |
108 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 9 | 36 | 2.314e-07 | 9.971e-06 |
109 | REGULATION OF PROTEIN LOCALIZATION | 52 | 950 | 2.414e-07 | 1.031e-05 |
110 | PROTEIN K11 LINKED UBIQUITINATION | 8 | 27 | 2.602e-07 | 1.101e-05 |
111 | DIGESTIVE SYSTEM DEVELOPMENT | 17 | 148 | 2.723e-07 | 1.142e-05 |
112 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 54 | 1008 | 2.761e-07 | 1.147e-05 |
113 | NEGATIVE REGULATION OF CELL DIVISION | 11 | 60 | 3.188e-07 | 1.313e-05 |
114 | PROTEOLYSIS | 61 | 1208 | 3.404e-07 | 1.39e-05 |
115 | PROTEIN UBIQUITINATION INVOLVED IN UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 16 | 134 | 3.584e-07 | 1.437e-05 |
116 | NEGATIVE REGULATION OF CHROMOSOME SEGREGATION | 8 | 28 | 3.561e-07 | 1.437e-05 |
117 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 67 | 1381 | 3.662e-07 | 1.456e-05 |
118 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 17 | 152 | 4.002e-07 | 1.578e-05 |
119 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 75 | 1618 | 4.041e-07 | 1.58e-05 |
120 | IMMUNE SYSTEM PROCESS | 87 | 1984 | 4.567e-07 | 1.742e-05 |
121 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 56 | 1079 | 4.543e-07 | 1.742e-05 |
122 | GLAND DEVELOPMENT | 29 | 395 | 4.549e-07 | 1.742e-05 |
123 | RESPONSE TO GAMMA RADIATION | 10 | 50 | 4.701e-07 | 1.764e-05 |
124 | CATABOLIC PROCESS | 80 | 1773 | 4.664e-07 | 1.764e-05 |
125 | MITOTIC SISTER CHROMATID SEGREGATION | 13 | 91 | 5.648e-07 | 2.103e-05 |
126 | POSITIVE REGULATION OF GENE EXPRESSION | 78 | 1733 | 7.336e-07 | 2.709e-05 |
127 | REGULATION OF DNA REPLICATION | 17 | 161 | 9.078e-07 | 3.326e-05 |
128 | SISTER CHROMATID COHESION | 14 | 111 | 9.869e-07 | 3.587e-05 |
129 | RESPONSE TO ENDOGENOUS STIMULUS | 68 | 1450 | 1.005e-06 | 3.626e-05 |
130 | RESPONSE TO IONIZING RADIATION | 16 | 145 | 1.051e-06 | 3.763e-05 |
131 | REGULATION OF CELL GROWTH | 28 | 391 | 1.178e-06 | 4.164e-05 |
132 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 9 | 43 | 1.181e-06 | 4.164e-05 |
133 | PHOSPHORYLATION | 60 | 1228 | 1.268e-06 | 4.404e-05 |
134 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 40 | 684 | 1.267e-06 | 4.404e-05 |
135 | REGULATION OF ORGAN MORPHOGENESIS | 21 | 242 | 1.295e-06 | 4.463e-05 |
136 | DNA DEPENDENT DNA REPLICATION | 13 | 99 | 1.512e-06 | 5.172e-05 |
137 | REGULATION OF MEMBRANE PERMEABILITY | 11 | 70 | 1.597e-06 | 5.423e-05 |
138 | NEGATIVE REGULATION OF MITOTIC NUCLEAR DIVISION | 8 | 34 | 1.816e-06 | 6.124e-05 |
139 | NEGATIVE REGULATION OF NUCLEAR DIVISION | 9 | 46 | 2.155e-06 | 7.214e-05 |
140 | SPINDLE CHECKPOINT | 7 | 25 | 2.286e-06 | 7.598e-05 |
141 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 48 | 917 | 2.518e-06 | 8.309e-05 |
142 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 26 | 363 | 2.826e-06 | 9.259e-05 |
143 | POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 8 | 36 | 2.894e-06 | 9.415e-05 |
144 | POSITIVE REGULATION OF CELL PROLIFERATION | 44 | 814 | 2.966e-06 | 9.55e-05 |
145 | PEPTIDYL AMINO ACID MODIFICATION | 45 | 841 | 2.976e-06 | 9.55e-05 |
146 | MACROMOLECULE CATABOLIC PROCESS | 48 | 926 | 3.288e-06 | 0.0001048 |
147 | POSITIVE REGULATION OF MITOTIC CELL CYCLE | 14 | 123 | 3.419e-06 | 0.0001082 |
148 | LEUKOCYTE ACTIVATION | 28 | 414 | 3.568e-06 | 0.0001122 |
149 | REGENERATION | 16 | 161 | 4.205e-06 | 0.0001304 |
150 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 32 | 514 | 4.183e-06 | 0.0001304 |
151 | POSITIVE REGULATION OF STEM CELL DIFFERENTIATION | 9 | 50 | 4.473e-06 | 0.0001378 |
152 | NEGATIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 13 | 109 | 4.524e-06 | 0.0001382 |
153 | RESPONSE TO UV | 14 | 126 | 4.552e-06 | 0.0001382 |
154 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 51 | 1021 | 4.575e-06 | 0.0001382 |
155 | CELL ACTIVATION | 34 | 568 | 4.912e-06 | 0.0001475 |
156 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 22 | 285 | 5.013e-06 | 0.0001495 |
157 | TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 12 | 95 | 5.759e-06 | 0.0001707 |
158 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 29 | 6.79e-06 | 0.000198 |
159 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 29 | 6.79e-06 | 0.000198 |
160 | ORGAN MORPHOGENESIS | 44 | 841 | 6.807e-06 | 0.000198 |
161 | TUBE DEVELOPMENT | 33 | 552 | 6.961e-06 | 0.0002012 |
162 | REPLICATIVE SENESCENCE | 5 | 12 | 7.5e-06 | 0.0002154 |
163 | RESPONSE TO DRUG | 28 | 431 | 7.622e-06 | 0.0002176 |
164 | POSITIVE REGULATION OF CHROMOSOME ORGANIZATION | 15 | 150 | 7.748e-06 | 0.0002198 |
165 | REGULATION OF GROWTH | 36 | 633 | 8.086e-06 | 0.000228 |
166 | REGULATION OF DNA METABOLIC PROCESS | 24 | 340 | 8.691e-06 | 0.0002436 |
167 | LYMPHOCYTE ACTIVATION | 24 | 342 | 9.588e-06 | 0.0002671 |
168 | RESPONSE TO RADIATION | 27 | 413 | 9.883e-06 | 0.0002737 |
169 | NEGATIVE REGULATION OF DNA REPLICATION | 9 | 55 | 1.013e-05 | 0.0002789 |
170 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 29 | 465 | 1.143e-05 | 0.0003129 |
171 | RESPONSE TO LIPID | 45 | 888 | 1.196e-05 | 0.0003254 |
172 | CELLULAR RESPONSE TO RADIATION | 14 | 137 | 1.209e-05 | 0.000327 |
173 | CELLULAR CATABOLIC PROCESS | 60 | 1322 | 1.265e-05 | 0.0003403 |
174 | NEGATIVE REGULATION OF PHOSPHORYLATION | 27 | 422 | 1.455e-05 | 0.000389 |
175 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 54 | 1152 | 1.465e-05 | 0.0003896 |
176 | CHROMOSOME ORGANIZATION | 49 | 1009 | 1.501e-05 | 0.0003946 |
177 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 33 | 573 | 1.5e-05 | 0.0003946 |
178 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 20 | 263 | 1.669e-05 | 0.0004362 |
179 | PROTEIN POLYUBIQUITINATION | 19 | 243 | 1.835e-05 | 0.0004769 |
180 | POSITIVE REGULATION OF TRANSPORT | 46 | 936 | 2.063e-05 | 0.0005333 |
181 | POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 7 | 34 | 2.094e-05 | 0.0005383 |
182 | ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE ANTIGEN VIA MHC CLASS I | 11 | 91 | 2.149e-05 | 0.0005495 |
183 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 41 | 799 | 2.218e-05 | 0.0005639 |
184 | MITOCHONDRIAL MEMBRANE ORGANIZATION | 11 | 92 | 2.386e-05 | 0.0006033 |
185 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 17 | 207 | 2.686e-05 | 0.0006756 |
186 | DIGESTIVE TRACT MORPHOGENESIS | 8 | 48 | 2.753e-05 | 0.0006886 |
187 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 60 | 1360 | 2.917e-05 | 0.0007258 |
188 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 31 | 541 | 2.993e-05 | 0.0007369 |
189 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 31 | 541 | 2.993e-05 | 0.0007369 |
190 | REGULATION OF INTRACELLULAR TRANSPORT | 34 | 621 | 3.143e-05 | 0.0007696 |
191 | POSITIVE REGULATION OF CHROMOSOME SEGREGATION | 6 | 25 | 3.269e-05 | 0.0007964 |
192 | REGULATION OF CELLULAR LOCALIZATION | 57 | 1277 | 3.391e-05 | 0.0008217 |
193 | REGULATION OF STEM CELL DIFFERENTIATION | 12 | 113 | 3.429e-05 | 0.0008268 |
194 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 24 | 370 | 3.472e-05 | 0.0008328 |
195 | NEGATIVE REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 9 | 64 | 3.575e-05 | 0.0008402 |
196 | TUBE MORPHOGENESIS | 22 | 323 | 3.53e-05 | 0.0008402 |
197 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 40 | 788 | 3.562e-05 | 0.0008402 |
198 | CIRCULATORY SYSTEM DEVELOPMENT | 40 | 788 | 3.562e-05 | 0.0008402 |
199 | EPITHELIAL CELL DIFFERENTIATION | 29 | 495 | 3.622e-05 | 0.0008468 |
200 | POSITIVE REGULATION OF CELL DIVISION | 13 | 132 | 3.647e-05 | 0.0008485 |
201 | REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS | 5 | 16 | 3.798e-05 | 0.0008749 |
202 | CELLULAR RESPONSE TO ANTIBIOTIC | 5 | 16 | 3.798e-05 | 0.0008749 |
203 | RESPONSE TO STEROID HORMONE | 29 | 497 | 3.895e-05 | 0.0008927 |
204 | REGULATION OF RESPONSE TO STRESS | 63 | 1468 | 4.144e-05 | 0.0009453 |
205 | CELLULAR RESPONSE TO UV | 9 | 66 | 4.592e-05 | 0.001037 |
206 | ANTIGEN PROCESSING AND PRESENTATION OF EXOGENOUS PEPTIDE ANTIGEN VIA MHC CLASS I | 9 | 66 | 4.592e-05 | 0.001037 |
207 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 11 | 99 | 4.761e-05 | 0.001065 |
208 | REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 11 | 99 | 4.761e-05 | 0.001065 |
209 | GLIOGENESIS | 15 | 175 | 4.842e-05 | 0.001078 |
210 | GLIAL CELL DIFFERENTIATION | 13 | 136 | 4.99e-05 | 0.001106 |
211 | CELLULAR RESPONSE TO IONIZING RADIATION | 8 | 52 | 5.017e-05 | 0.001106 |
212 | ORGAN REGENERATION | 10 | 83 | 5.217e-05 | 0.001121 |
213 | POSITIVE REGULATION OF NEURON DEATH | 9 | 67 | 5.185e-05 | 0.001121 |
214 | REGULATION OF HYDROLASE ACTIVITY | 58 | 1327 | 5.189e-05 | 0.001121 |
215 | RESPONSE TO ESTROGEN | 17 | 218 | 5.177e-05 | 0.001121 |
216 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 17 | 218 | 5.177e-05 | 0.001121 |
217 | POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 11 | 100 | 5.227e-05 | 0.001121 |
218 | NEGATIVE REGULATION OF CELL AGING | 5 | 17 | 5.267e-05 | 0.001124 |
219 | SKELETAL SYSTEM DEVELOPMENT | 27 | 455 | 5.392e-05 | 0.001146 |
220 | POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 9 | 68 | 5.842e-05 | 0.001236 |
221 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 69 | 1672 | 5.907e-05 | 0.001244 |
222 | REGULATION OF MICROTUBULE BASED PROCESS | 18 | 243 | 6.155e-05 | 0.00129 |
223 | REGULATION OF TRANSPORT | 73 | 1804 | 6.608e-05 | 0.001379 |
224 | NEGATIVE REGULATION OF ORGANELLE ORGANIZATION | 24 | 387 | 7.052e-05 | 0.001465 |
225 | POSITIVE REGULATION OF DNA REPLICATION | 10 | 86 | 7.091e-05 | 0.001466 |
226 | REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 15 | 181 | 7.125e-05 | 0.001467 |
227 | NEGATIVE REGULATION OF CELL COMMUNICATION | 53 | 1192 | 7.183e-05 | 0.001472 |
228 | LEUKOCYTE DIFFERENTIATION | 20 | 292 | 7.339e-05 | 0.001491 |
229 | CELLULAR COMPONENT DISASSEMBLY | 29 | 515 | 7.331e-05 | 0.001491 |
230 | NEGATIVE REGULATION OF CELL DEATH | 42 | 872 | 7.487e-05 | 0.001515 |
231 | CRANIAL SKELETAL SYSTEM DEVELOPMENT | 8 | 55 | 7.588e-05 | 0.001528 |
232 | ANGIOGENESIS | 20 | 293 | 7.693e-05 | 0.001543 |
233 | ENDODERM DEVELOPMENT | 9 | 71 | 8.248e-05 | 0.001647 |
234 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 13 | 144 | 9.011e-05 | 0.001792 |
235 | POSITIVE REGULATION OF DNA METABOLIC PROCESS | 15 | 185 | 9.127e-05 | 0.001807 |
236 | APOPTOTIC MITOCHONDRIAL CHANGES | 8 | 57 | 9.846e-05 | 0.001941 |
237 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 23 | 372 | 0.0001039 | 0.00204 |
238 | MESONEPHROS DEVELOPMENT | 10 | 90 | 0.0001045 | 0.002044 |
239 | INTERSPECIES INTERACTION BETWEEN ORGANISMS | 34 | 662 | 0.0001101 | 0.002134 |
240 | SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM | 34 | 662 | 0.0001101 | 0.002134 |
241 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 30 | 554 | 0.0001111 | 0.002145 |
242 | EMBRYONIC PATTERN SPECIFICATION | 8 | 58 | 0.0001117 | 0.002147 |
243 | REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 13 | 148 | 0.0001191 | 0.00228 |
244 | NEGATIVE REGULATION OF CELLULAR SENESCENCE | 4 | 11 | 0.0001232 | 0.00235 |
245 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 12 | 129 | 0.0001254 | 0.002381 |
246 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 28 | 505 | 0.0001263 | 0.002389 |
247 | PROTEIN COMPLEX SUBUNIT ORGANIZATION | 63 | 1527 | 0.0001284 | 0.00242 |
248 | RESPONSE TO REACTIVE OXYGEN SPECIES | 15 | 191 | 0.0001305 | 0.002448 |
249 | NEGATIVE REGULATION OF CELL GROWTH | 14 | 170 | 0.0001317 | 0.002451 |
250 | DNA REPAIR | 27 | 480 | 0.0001314 | 0.002451 |
251 | ANTIGEN PROCESSING AND PRESENTATION | 16 | 213 | 0.0001324 | 0.002454 |
252 | NEGATIVE REGULATION OF DNA METABOLIC PROCESS | 11 | 111 | 0.0001356 | 0.002504 |
253 | EXOCRINE SYSTEM DEVELOPMENT | 7 | 45 | 0.0001384 | 0.002545 |
254 | SALIVARY GLAND DEVELOPMENT | 6 | 32 | 0.0001436 | 0.00261 |
255 | REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION | 8 | 60 | 0.0001425 | 0.00261 |
256 | REGULATION OF BINDING | 19 | 283 | 0.0001433 | 0.00261 |
257 | BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE | 12 | 131 | 0.0001452 | 0.002628 |
258 | REGULATION OF DNA BIOSYNTHETIC PROCESS | 10 | 94 | 0.0001508 | 0.00272 |
259 | EMBRYONIC CRANIAL SKELETON MORPHOGENESIS | 7 | 46 | 0.0001596 | 0.002868 |
260 | MITOCHONDRION ORGANIZATION | 31 | 594 | 0.000166 | 0.002971 |
261 | CELLULAR RESPONSE TO STEROID HORMONE STIMULUS | 16 | 218 | 0.000173 | 0.003084 |
262 | REGULATION OF MACROPHAGE CYTOKINE PRODUCTION | 4 | 12 | 0.0001811 | 0.003204 |
263 | POSITIVE REGULATION OF SMAD PROTEIN IMPORT INTO NUCLEUS | 4 | 12 | 0.0001811 | 0.003204 |
264 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 7 | 47 | 0.0001835 | 0.003233 |
265 | MITOCHONDRIAL TRANSPORT | 14 | 177 | 0.0002013 | 0.003517 |
266 | ANTIGEN PROCESSING AND PRESENTATION OF PEPTIDE ANTIGEN | 14 | 177 | 0.0002013 | 0.003517 |
267 | CELLULAR RESPONSE TO INORGANIC SUBSTANCE | 13 | 156 | 0.0002018 | 0.003517 |
268 | POSITIVE REGULATION OF PATHWAY RESTRICTED SMAD PROTEIN PHOSPHORYLATION | 7 | 48 | 0.0002101 | 0.003647 |
269 | RESPONSE TO CYTOKINE | 35 | 714 | 0.0002142 | 0.003705 |
270 | SKELETAL SYSTEM MORPHOGENESIS | 15 | 201 | 0.0002285 | 0.003939 |
271 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 76 | 1977 | 0.0002343 | 0.004023 |
272 | REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 10 | 100 | 0.0002518 | 0.004307 |
273 | MITOTIC CELL CYCLE ARREST | 4 | 13 | 0.0002563 | 0.004369 |
274 | MACROMOLECULAR COMPLEX DISASSEMBLY | 14 | 182 | 0.0002686 | 0.004561 |
275 | NEGATIVE REGULATION OF KINASE ACTIVITY | 17 | 250 | 0.0002724 | 0.004609 |
276 | NEGATIVE REGULATION OF CELLULAR RESPONSE TO TRANSFORMING GROWTH FACTOR BETA STIMULUS | 8 | 66 | 0.0002797 | 0.004698 |
277 | NEGATIVE REGULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 8 | 66 | 0.0002797 | 0.004698 |
278 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 11 | 121 | 0.0002908 | 0.004867 |
279 | RESPONSE TO INORGANIC SUBSTANCE | 26 | 479 | 0.0003033 | 0.005059 |
280 | REPRODUCTION | 54 | 1297 | 0.0003212 | 0.005337 |
281 | REGULATION OF CYTOPLASMIC TRANSPORT | 26 | 481 | 0.0003233 | 0.005353 |
282 | REGULATION OF CYTOKINE PRODUCTION | 29 | 563 | 0.0003322 | 0.005462 |
283 | POSITIVE REGULATION OF CHROMATIN MODIFICATION | 9 | 85 | 0.0003321 | 0.005462 |
284 | POSITIVE REGULATION OF KINASE ACTIVITY | 26 | 482 | 0.0003337 | 0.005467 |
285 | LEUKOCYTE CELL CELL ADHESION | 17 | 255 | 0.000343 | 0.0056 |
286 | POSITIVE REGULATION OF MITOTIC SISTER CHROMATID SEPARATION | 4 | 14 | 0.0003516 | 0.005622 |
287 | POSITIVE REGULATION OF MITOTIC METAPHASE ANAPHASE TRANSITION | 4 | 14 | 0.0003516 | 0.005622 |
288 | CELLULAR RESPONSE TO LIPID | 25 | 457 | 0.000351 | 0.005622 |
289 | POSITIVE REGULATION OF METAPHASE ANAPHASE TRANSITION OF CELL CYCLE | 4 | 14 | 0.0003516 | 0.005622 |
290 | CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES | 10 | 104 | 0.0003466 | 0.005622 |
291 | LYMPHOCYTE DIFFERENTIATION | 15 | 209 | 0.0003477 | 0.005622 |
292 | RESPONSE TO LIGHT STIMULUS | 18 | 280 | 0.0003604 | 0.005743 |
293 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 9 | 86 | 0.0003626 | 0.005759 |
294 | CELLULAR RESPONSE TO TOXIC SUBSTANCE | 5 | 25 | 0.0003816 | 0.005938 |
295 | REGULATION OF TRANSFORMING GROWTH FACTOR BETA PRODUCTION | 5 | 25 | 0.0003816 | 0.005938 |
296 | CARBOHYDRATE DERIVATIVE BIOSYNTHETIC PROCESS | 30 | 595 | 0.0003769 | 0.005938 |
297 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 22 | 381 | 0.0003788 | 0.005938 |
298 | MITOTIC SPINDLE ORGANIZATION | 8 | 69 | 0.0003807 | 0.005938 |
299 | IRON ION HOMEOSTASIS | 8 | 69 | 0.0003807 | 0.005938 |
300 | POSITIVE REGULATION OF BIOMINERAL TISSUE DEVELOPMENT | 6 | 38 | 0.000384 | 0.005956 |
301 | TISSUE REMODELING | 9 | 87 | 0.0003954 | 0.006052 |
302 | MORPHOGENESIS OF A BRANCHING STRUCTURE | 13 | 167 | 0.0003926 | 0.006052 |
303 | INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR | 7 | 53 | 0.0003938 | 0.006052 |
304 | MYELOID CELL DIFFERENTIATION | 14 | 189 | 0.0003947 | 0.006052 |
305 | RESPONSE TO ESTRADIOL | 12 | 146 | 0.0003984 | 0.006078 |
306 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 11 | 126 | 0.0004126 | 0.006274 |
307 | TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 14 | 190 | 0.0004164 | 0.00631 |
308 | RESPONSE TO METAL ION | 20 | 333 | 0.0004196 | 0.006338 |
309 | RESPONSE TO EXTERNAL STIMULUS | 70 | 1821 | 0.0004244 | 0.006381 |
310 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 15 | 213 | 0.0004252 | 0.006381 |
311 | RESPONSE TO NITROGEN COMPOUND | 39 | 859 | 0.0004415 | 0.006605 |
312 | B CELL DIFFERENTIATION | 9 | 89 | 0.0004684 | 0.006961 |
313 | SENSORY ORGAN DEVELOPMENT | 26 | 493 | 0.0004693 | 0.006961 |
314 | ACTIVATION OF ANAPHASE PROMOTING COMPLEX ACTIVITY | 4 | 15 | 0.0004697 | 0.006961 |
315 | HEPATICOBILIARY SYSTEM DEVELOPMENT | 11 | 128 | 0.000472 | 0.006973 |
316 | VASCULATURE DEVELOPMENT | 25 | 469 | 0.0005137 | 0.007563 |
317 | REGULATION OF PROTEIN COMPLEX DISASSEMBLY | 15 | 217 | 0.0005169 | 0.007587 |
318 | REGULATION OF MITOCHONDRION ORGANIZATION | 15 | 218 | 0.0005423 | 0.007935 |
319 | CELLULAR RESPONSE TO LIGHT STIMULUS | 9 | 91 | 0.0005521 | 0.008052 |
320 | SMAD PROTEIN SIGNAL TRANSDUCTION | 7 | 56 | 0.0005545 | 0.008063 |
321 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 12 | 152 | 0.0005733 | 0.008311 |
322 | REGULATION OF DNA DEPENDENT DNA REPLICATION | 6 | 41 | 0.000586 | 0.008468 |
323 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 15 | 220 | 0.0005963 | 0.00859 |
324 | REGULATION OF CYTOSKELETON ORGANIZATION | 26 | 502 | 0.0006142 | 0.008821 |
325 | RESPONSE TO AMINO ACID | 10 | 112 | 0.0006264 | 0.008968 |
326 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 40 | 905 | 0.0006319 | 0.009019 |
327 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 12 | 154 | 0.0006443 | 0.009169 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | ENZYME BINDING | 93 | 1737 | 6.383e-12 | 5.93e-09 |
2 | CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE REGULATOR ACTIVITY | 10 | 28 | 9.978e-10 | 4.635e-07 |
3 | PROTEIN COMPLEX BINDING | 56 | 935 | 3.585e-09 | 1.11e-06 |
4 | KINASE BINDING | 39 | 606 | 1.569e-07 | 3.643e-05 |
5 | MACROMOLECULAR COMPLEX BINDING | 68 | 1399 | 2.766e-07 | 5.14e-05 |
6 | PROTEIN KINASE ACTIVITY | 38 | 640 | 1.64e-06 | 0.0002539 |
7 | IDENTICAL PROTEIN BINDING | 58 | 1209 | 3.418e-06 | 0.0004536 |
8 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 21 | 264 | 5.154e-06 | 0.0005985 |
9 | CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 5 | 12 | 7.5e-06 | 0.0007742 |
10 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 7 | 30 | 8.661e-06 | 0.0008046 |
11 | TRANSCRIPTION FACTOR BINDING | 31 | 524 | 1.621e-05 | 0.001369 |
12 | CORE PROMOTER BINDING | 14 | 152 | 3.91e-05 | 0.002622 |
13 | KINASE ACTIVITY | 42 | 842 | 3.396e-05 | 0.002622 |
14 | DOUBLE STRANDED DNA BINDING | 39 | 764 | 3.952e-05 | 0.002622 |
15 | SMAD BINDING | 9 | 72 | 9.214e-05 | 0.005046 |
16 | PROTEIN DIMERIZATION ACTIVITY | 51 | 1149 | 0.0001032 | 0.005046 |
17 | KINASE REGULATOR ACTIVITY | 15 | 186 | 9.698e-05 | 0.005046 |
18 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 26 | 445 | 9.508e-05 | 0.005046 |
19 | CORE PROMOTER PROXIMAL REGION DNA BINDING | 23 | 371 | 9.982e-05 | 0.005046 |
20 | I SMAD BINDING | 4 | 11 | 0.0001232 | 0.005725 |
21 | REGULATORY REGION NUCLEIC ACID BINDING | 39 | 818 | 0.0001669 | 0.007046 |
22 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 45 | 992 | 0.0001646 | 0.007046 |
23 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 32 | 629 | 0.0002069 | 0.008009 |
24 | CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY | 6 | 34 | 0.0002041 | 0.008009 |
25 | R SMAD BINDING | 5 | 23 | 0.0002521 | 0.009369 |
26 | PROTEIN HOMODIMERIZATION ACTIVITY | 35 | 722 | 0.0002639 | 0.009382 |
27 | TRANSFORMING GROWTH FACTOR BETA RECEPTOR BINDING | 7 | 50 | 0.0002727 | 0.009382 |
28 | RIBONUCLEOTIDE BINDING | 72 | 1860 | 0.0002848 | 0.009436 |
29 | ENZYME REGULATOR ACTIVITY | 43 | 959 | 0.0002946 | 0.009436 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | ANAPHASE PROMOTING COMPLEX | 10 | 22 | 5.649e-11 | 3.299e-08 |
2 | NUCLEAR UBIQUITIN LIGASE COMPLEX | 12 | 42 | 4.008e-10 | 1.17e-07 |
3 | TRANSCRIPTION FACTOR COMPLEX | 26 | 298 | 6.404e-08 | 9.35e-06 |
4 | CYCLIN DEPENDENT PROTEIN KINASE HOLOENZYME COMPLEX | 9 | 31 | 5.557e-08 | 9.35e-06 |
5 | CHROMOSOMAL REGION | 27 | 330 | 1.336e-07 | 1.318e-05 |
6 | SPINDLE | 25 | 289 | 1.354e-07 | 1.318e-05 |
7 | ANCHORING JUNCTION | 34 | 489 | 1.684e-07 | 1.405e-05 |
8 | NUCLEAR CHROMOSOME | 34 | 523 | 7.95e-07 | 5.804e-05 |
9 | CELL SUBSTRATE JUNCTION | 28 | 398 | 1.668e-06 | 0.0001082 |
10 | CHROMOSOME | 47 | 880 | 1.867e-06 | 0.000109 |
11 | SPINDLE POLE | 14 | 126 | 4.552e-06 | 0.0002215 |
12 | MCM COMPLEX | 5 | 11 | 4.47e-06 | 0.0002215 |
13 | CULLIN RING UBIQUITIN LIGASE COMPLEX | 14 | 150 | 3.375e-05 | 0.001516 |
14 | SPINDLE MIDZONE | 6 | 27 | 5.231e-05 | 0.002182 |
15 | MITOTIC SPINDLE | 8 | 55 | 7.588e-05 | 0.002664 |
16 | TRANSFERASE COMPLEX | 36 | 703 | 7.355e-05 | 0.002664 |
17 | CHROMATIN | 26 | 441 | 8.212e-05 | 0.002664 |
18 | CHROMOSOME TELOMERIC REGION | 14 | 162 | 7.858e-05 | 0.002664 |
19 | PROTEIN KINASE COMPLEX | 10 | 90 | 0.0001045 | 0.003214 |
20 | COHESIN COMPLEX | 4 | 11 | 0.0001232 | 0.003427 |
21 | MHC CLASS I PROTEIN COMPLEX | 4 | 11 | 0.0001232 | 0.003427 |
22 | NUCLEAR CHROMOSOME TELOMERIC REGION | 12 | 132 | 0.000156 | 0.004142 |
23 | CONDENSED CHROMOSOME | 15 | 195 | 0.0001641 | 0.004166 |
24 | CONDENSED CHROMOSOME OUTER KINETOCHORE | 4 | 12 | 0.0001811 | 0.004407 |
25 | PERINUCLEAR REGION OF CYTOPLASM | 32 | 642 | 0.0002969 | 0.006936 |
26 | CONDENSED NUCLEAR CHROMOSOME | 9 | 85 | 0.0003321 | 0.007459 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | Cell_cycle_hsa04110 | 85 | 124 | 6.009e-107 | 3.125e-105 | |
2 | Cellular_senescence_hsa04218 | 39 | 160 | 3.808e-27 | 9.902e-26 | |
3 | Oocyte_meiosis_hsa04114 | 29 | 124 | 6.074e-20 | 1.053e-18 | |
4 | p53_signaling_pathway_hsa04115 | 18 | 68 | 6.917e-14 | 8.992e-13 | |
5 | FoxO_signaling_pathway_hsa04068 | 22 | 132 | 3.046e-12 | 3.168e-11 | |
6 | TGF_beta_signaling_pathway_hsa04350 | 17 | 84 | 3.733e-11 | 3.236e-10 | |
7 | Hippo_signaling_pathway_hsa04390 | 20 | 154 | 2.877e-09 | 2.137e-08 | |
8 | PI3K_Akt_signaling_pathway_hsa04151 | 29 | 352 | 3.93e-08 | 2.554e-07 | |
9 | Wnt_signaling_pathway_hsa04310 | 16 | 146 | 1.153e-06 | 6.664e-06 | |
10 | ErbB_signaling_pathway_hsa04012 | 12 | 85 | 1.749e-06 | 9.096e-06 | |
11 | Adherens_junction_hsa04520 | 10 | 72 | 1.48e-05 | 6.995e-05 | |
12 | HIF_1_signaling_pathway_hsa04066 | 11 | 100 | 5.227e-05 | 0.0002265 | |
13 | Focal_adhesion_hsa04510 | 16 | 199 | 5.941e-05 | 0.0002376 | |
14 | Jak_STAT_signaling_pathway_hsa04630 | 14 | 162 | 7.858e-05 | 0.0002919 | |
15 | Apoptosis_hsa04210 | 12 | 138 | 0.000237 | 0.0007926 | |
16 | MAPK_signaling_pathway_hsa04010 | 19 | 295 | 0.0002439 | 0.0007926 | |
17 | Signaling_pathways_regulating_pluripotency_of_stem_cells_hsa04550 | 11 | 139 | 0.0009421 | 0.002882 | |
18 | Ferroptosis_hsa04216 | 4 | 40 | 0.01898 | 0.05348 | |
19 | Calcium_signaling_pathway_hsa04020 | 10 | 182 | 0.01954 | 0.05348 | |
20 | Endocytosis_hsa04144 | 12 | 244 | 0.02444 | 0.06354 | |
21 | Hedgehog_signaling_pathway_hsa04340 | 4 | 47 | 0.03223 | 0.07982 | |
22 | Notch_signaling_pathway_hsa04330 | 4 | 48 | 0.03448 | 0.08149 | |
23 | Cytokine_cytokine_receptor_interaction_hsa04060 | 12 | 270 | 0.04718 | 0.1067 | |
24 | Tight_junction_hsa04530 | 8 | 170 | 0.07272 | 0.1576 | |
25 | Ras_signaling_pathway_hsa04014 | 10 | 232 | 0.0775 | 0.1612 | |
26 | Rap1_signaling_pathway_hsa04015 | 9 | 206 | 0.08522 | 0.1656 | |
27 | Mitophagy_animal_hsa04137 | 4 | 65 | 0.08596 | 0.1656 | |
28 | Regulation_of_actin_cytoskeleton_hsa04810 | 9 | 208 | 0.08918 | 0.1656 | |
29 | Apelin_signaling_pathway_hsa04371 | 6 | 137 | 0.1419 | 0.2544 | |
30 | ECM_receptor_interaction_hsa04512 | 4 | 82 | 0.1602 | 0.2776 | |
31 | Gap_junction_hsa04540 | 4 | 88 | 0.1906 | 0.3146 | |
32 | mTOR_signaling_pathway_hsa04150 | 6 | 151 | 0.1936 | 0.3146 | |
33 | AMPK_signaling_pathway_hsa04152 | 5 | 121 | 0.201 | 0.3167 | |
34 | NF_kappa_B_signaling_pathway_hsa04064 | 4 | 95 | 0.2281 | 0.3489 | |
35 | Necroptosis_hsa04217 | 6 | 164 | 0.247 | 0.3616 | |
36 | Phosphatidylinositol_signaling_system_hsa04070 | 4 | 99 | 0.2504 | 0.3616 | |
37 | TNF_signaling_pathway_hsa04668 | 4 | 108 | 0.3018 | 0.4242 | |
38 | Cell_adhesion_molecules_.CAMs._hsa04514 | 5 | 145 | 0.317 | 0.4294 | |
39 | Phospholipase_D_signaling_pathway_hsa04072 | 5 | 146 | 0.322 | 0.4294 | |
40 | Phagosome_hsa04145 | 5 | 152 | 0.3525 | 0.4583 | |
41 | cGMP_PKG_signaling_pathway_hsa04022 | 5 | 163 | 0.4087 | 0.5183 | |
42 | VEGF_signaling_pathway_hsa04370 | 2 | 59 | 0.4501 | 0.5573 | |
43 | Lysosome_hsa04142 | 3 | 123 | 0.6159 | 0.7117 | |
44 | Sphingolipid_signaling_pathway_hsa04071 | 2 | 118 | 0.8104 | 0.8966 | |
45 | Autophagy_animal_hsa04140 | 2 | 128 | 0.8447 | 0.915 | |
46 | cAMP_signaling_pathway_hsa04024 | 3 | 198 | 0.887 | 0.9225 | |
47 | Neuroactive_ligand_receptor_interaction_hsa04080 | 2 | 278 | 0.9942 | 1 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | UCA1 |
hsa-miR-103a-3p;hsa-miR-1224-5p;hsa-miR-136-5p;hsa-miR-140-3p;hsa-miR-148b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-185-5p;hsa-miR-191-5p;hsa-miR-26a-5p;hsa-miR-3065-5p;hsa-miR-33b-5p;hsa-miR-340-5p;hsa-miR-362-5p;hsa-miR-374a-5p;hsa-miR-374b-5p;hsa-miR-500a-5p;hsa-miR-539-5p;hsa-miR-582-5p;hsa-miR-671-5p;hsa-miR-7-1-3p | 21 | CDK6 | Sponge network | 1.481 | 0.28957 | 0.112 | 0.76976 | 0.48 |
2 | EGOT |
hsa-miR-103a-3p;hsa-miR-1224-5p;hsa-miR-136-5p;hsa-miR-137;hsa-miR-148b-3p;hsa-miR-148b-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-185-5p;hsa-miR-29b-3p;hsa-miR-33b-5p;hsa-miR-340-5p;hsa-miR-421;hsa-miR-501-3p;hsa-miR-7-1-3p | 15 | CDK6 | Sponge network | -1.196 | 0.1622 | 0.112 | 0.76976 | 0.394 |
3 | RFPL1S | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-20a-5p;hsa-miR-224-3p;hsa-miR-224-5p;hsa-miR-26b-5p;hsa-miR-27a-3p;hsa-miR-28-3p;hsa-miR-34a-5p;hsa-miR-429;hsa-miR-92a-3p;hsa-miR-93-5p | 19 | SMAD4 | Sponge network | -0.457 | 0.43621 | -0.501 | 0.1224 | 0.384 |
4 | UCA1 |
hsa-miR-101-5p;hsa-miR-125a-5p;hsa-miR-126-5p;hsa-miR-132-3p;hsa-miR-153-3p;hsa-miR-154-3p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-299-3p;hsa-miR-340-5p;hsa-miR-495-3p;hsa-miR-590-3p;hsa-miR-7-1-3p | 14 | TFDP2 | Sponge network | 1.481 | 0.28957 | 0.25 | 0.34904 | 0.372 |
5 | UCA1 |
hsa-miR-135a-5p;hsa-miR-15a-5p;hsa-miR-16-5p;hsa-miR-186-5p;hsa-miR-20b-5p;hsa-miR-296-5p;hsa-miR-340-5p;hsa-miR-374a-5p;hsa-miR-374b-5p;hsa-miR-495-3p;hsa-miR-590-3p;hsa-miR-7-1-3p | 12 | CCND1 | Sponge network | 1.481 | 0.28957 | 1.037 | 0.01709 | 0.349 |
6 | DIO3OS |
hsa-let-7g-3p;hsa-miR-132-3p;hsa-miR-15a-5p;hsa-miR-188-5p;hsa-miR-212-3p;hsa-miR-29b-2-5p;hsa-miR-330-3p;hsa-miR-501-5p;hsa-miR-671-5p;hsa-miR-769-5p | 10 | SMAD3 | Sponge network | 1.18 | 0.0997 | -0.053 | 0.89869 | 0.344 |
7 | HCG11 |
hsa-miR-148b-3p;hsa-miR-186-5p;hsa-miR-200a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-301a-3p;hsa-miR-362-3p;hsa-miR-362-5p;hsa-miR-500b-5p;hsa-miR-590-3p | 10 | TGFB2 | Sponge network | -0.31 | 0.48859 | -0.527 | 0.43869 | 0.319 |
8 | PART1 |
hsa-miR-146a-5p;hsa-miR-146b-5p;hsa-miR-155-5p;hsa-miR-17-5p;hsa-miR-18a-5p;hsa-miR-199b-5p;hsa-miR-20a-5p;hsa-miR-21-3p;hsa-miR-214-5p;hsa-miR-224-3p;hsa-miR-224-5p;hsa-miR-2355-5p;hsa-miR-27a-3p;hsa-miR-27a-5p;hsa-miR-28-3p;hsa-miR-28-5p;hsa-miR-34a-5p;hsa-miR-34c-5p;hsa-miR-425-5p;hsa-miR-450b-5p;hsa-miR-508-3p;hsa-miR-92a-3p;hsa-miR-93-5p | 23 | SMAD4 | Sponge network | 2.634 | 0.03419 | -0.501 | 0.1224 | 0.314 |
9 | H19 |
hsa-miR-107;hsa-miR-136-3p;hsa-miR-148b-3p;hsa-miR-200a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-301a-3p;hsa-miR-454-3p;hsa-miR-495-3p;hsa-miR-589-3p | 10 | TGFB2 | Sponge network | -0.02 | 0.98077 | -0.527 | 0.43869 | 0.304 |
10 | HCG11 |
hsa-let-7a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-26a-5p;hsa-miR-26b-5p;hsa-miR-29a-3p;hsa-miR-29c-3p;hsa-miR-340-5p;hsa-miR-362-5p;hsa-miR-664a-3p | 10 | GSK3B | Sponge network | -0.31 | 0.48859 | -0.018 | 0.92408 | 0.254 |